

10/019791

Rec'd PCT/PTO 04 JAN 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: RTSP-0243

Inventors: Monia et al.

Serial No.: Not Yet Assigned

Filing Date: Herewith

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Title: Antisense Modulation of FADD Expression

#6/I.D.S

"Express Mail" Label No. EV017478015US

Date of Deposit: January 4, 2002

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box PCT, Washington, D.C. 20231.

By Jaffe Massey Licata
Typed Name: Jaffe Massey Licata, Reg. No. 32,257

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified

application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

- () In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

- () Certification in Accordance with §1.97(e) is set forth below; or

- () The fee of \$180.00 as set forth in §1.17(p) is attached.

- () In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(i)(1).

- () Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

- (**XX**) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified)

10/019791

Rec'd PCT/PTO 04 JAN 2002

are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. 09/357,072, filed July 19, 1999, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(**XX**) All listed references are in the English language.

Respectfully submitted,

Jane Massey Licata

Jane Massey Licata
Registration No. 32,257

Date: January 4, 2002

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

3

Sheet 03 of 03

[illegible]

10/019791

04 JAN 2002

#6/I.D.S

Sheet 01 of 03

Form PTO-1449 Modified		Docket No. RTSP-0243	Serial No. Not Yet Assigned
List of Patents and Publications Cited by Application (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Applicant Monia et al.	
		Filing Date Herewith	Group Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AA	Chinnaiyan et al., FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis, <i>Cell</i> , 1995, 81:505-512	
	AB	Chinnaiyan et al., FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis, <i>J. Biol. Chem.</i> , 1996, 271:4961-4965	
	AC	Choi et al., Lipopolysaccharide mediates endothelial apoptosis by a FADD-dependent pathway, <i>J. Biol. Chem.</i> , 1998, 273:20185-20188	
	AD	Herr et al., Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis, <i>Embo J.</i> , 1997, 16:6200-6208	
	AE	Kondo et al., FADD gene therapy for malignant gliomas in vitro and in vivo [In Process Citation], <i>Hum. Gene Ther.</i> , 1998, 9:1599-1608	
	AF	Newton et al., A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes, <i>Embo J.</i> , 1998, 17:706-718	
	AG	Schwandner et al., TNF receptor death domain-associated proteins TRADD and FADD signal activation of acid sphingomyelinase, <i>J. Biol. Chem.</i> , 1998, 273:5916-5922	
	AH	Thompson, Apoptosis in the pathogenesis and treatment of disease, <i>Science</i> , 1995, 267:1456-1462	
	AI	Walsh et al., A role for FADD in T cell activation and development, <i>Immunity</i> , 1998, 8:439-449	
	AJ	Yeh et al., FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis, <i>Science</i> , 1998, 279:1954-1958	
	AK	Zhang et al., Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1, <i>Nature</i> , 1998, 392:296-300	
EXAMINER		DATE CONSIDERED	

10/019791

J Rec'd PCT/PTO 04 JAN 2002

Sheet 02 of 03

Form PTO-1449 Modified		Docket No. RTSP-0243	Serial No. Not Yet Assigned
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Monia et al.	
		Filing Date Herewith	Group Not Yet Assigned
U.S. Department of Commerce			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AL	Micheau et al., "Fas Ligand-independent, FADD-mediated Activation of the Fas Death Pathway by Anticancer Drugs", <i>J. of Biological Chemistry</i> 1999 274:7987-7992	
EXAMINER		DATE CONSIDERED	